Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.32
(
0.79%
)
Bitcoin
76,921.52
(
-0.64%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 203263

Thursday, 11/09/2017 7:01:28 PM

Thursday, November 09, 2017 7:01:28 PM

Post# of 257580
PFNX drops development of Lucentis/Neulasta FoBs:

https://www.prnewswire.com/news-releases/pfenex-reports-third-quarter-2017-results-interim-pk-data-from-pf708-study-completion-of-process-development-milestone-on-jazz-program-and-provides-business-update-300553252.html

Pfenex has completed a strategic review of PF582 and PF529, biosimilar product candidates to Lucentis and Neulasta, respectively. ...While the market opportunities remain attractive, Pfenex has decided to pause development activities on PF582 and PF529 and focus development efforts elsewhere within the product portfolio until strategic partnerships for these candidates are forged.

LOL re the word, pause.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today